Literature DB >> 32241792

COVID-19 in a patient with systemic sclerosis treated with tocilizumab for SSc-ILD.

Carina Mihai1, Rucsandra Dobrota1, Maria Schröder1, Alexandru Garaiman1, Suzana Jordan1, Mike Oliver Becker1, Britta Maurer1, Oliver Distler2.   

Abstract

Entities:  

Keywords:  biological therapy; communicable diseases, imported; cytokines; pulmonary fibrosis; scleroderma, systemic

Mesh：

Substances：

Year:  2020        PMID： 32241792     DOI： 10.1136/annrheumdis-2020-217442

Source DB:  PubMed          Journal:  Ann Rheum Dis        ISSN： 0003-4967            Impact factor:   19.103


× No keyword cloud information.
  55 in total

Review 1.  Medication use during COVID-19: Review of recent evidence.

Authors:  T S Brandon Ng; Kori Leblanc; Darwin F Yeung; Teresa S M Tsang
Journal:  Can Fam Physician       Date:  2021-03       Impact factor: 3.275

2.  COVID-19 in Immunocompromised Hosts: What We Know So Far.

Authors:  Monica Fung; Jennifer M Babik
Journal:  Clin Infect Dis       Date:  2020-06-27       Impact factor: 9.079

3.  COVID-19 in Patients With Connective Tissue Disease-related Interstitial Lung Disease.

Authors:  Linh Truong; Lila Pourzand; Elizabeth R Volkmann
Journal:  J Rheumatol       Date:  2020-09-15       Impact factor: 4.666

4.  Rationale for the use of sphingosine analogues in COVID-19 patients.

Authors:  Deborah R Tasat; Juan S Yakisich
Journal:  Clin Med (Lond)       Date:  2020-11-03       Impact factor: 2.659

Review 5. 

Authors:  T S Brandon Ng; Kori Leblanc; Darwin F Yeung; Teresa S M Tsang
Journal:  Can Fam Physician       Date:  2021-03       Impact factor: 3.275

6.  He-Jie-Shen-Shi Decoction as an Adjuvant Therapy on Severe Coronavirus Disease 2019: A Retrospective Cohort and Potential Mechanistic Study.

Authors:  Haibo Hu; Kun Wang; Li Wang; Yanjun Du; Juan Chen; Yongchun Li; Chuanbo Fan; Ning Li; Ying Sun; Shenghao Tu; Xuechao Lu; Zhaoshan Zhou; Huantian Cui
Journal:  Front Pharmacol       Date:  2021-06-18       Impact factor: 5.810

7.  Low symptomatic COVID-19 in an elderly patient with follicular lymphoma treated with rituximab-based immunotherapy: A case report.

Authors:  Stanisław Łącki; Kinga Wyżgolik; Michał Nicze; Sylwia Georgiew-Nadziakiewicz; Jerzy Chudek; Kamil Wdowiak
Journal:  World J Clin Cases       Date:  2021-06-26       Impact factor: 1.337

Review 8.  Targeting the Immune System for Pulmonary Inflammation and Cardiovascular Complications in COVID-19 Patients.

Authors:  Serena Colafrancesco; Rossana Scrivo; Cristiana Barbati; Fabrizio Conti; Roberta Priori
Journal:  Front Immunol       Date:  2020-06-23       Impact factor: 7.561

9.  Safety and efficacy of anti-il6-receptor tocilizumab use in severe and critical patients affected by coronavirus disease 2019: A comparative analysis.

Authors:  Roberto Rossotti; Giovanna Travi; Nicola Ughi; Matteo Corradin; Chiara Baiguera; Roberto Fumagalli; Maurizio Bottiroli; Michele Mondino; Marco Merli; Andrea Bellone; Andriano Basile; Ruggero Ruggeri; Fabrizio Colombo; Mauro Moreno; Stefano Pastori; Carlo Federico Perno; Paolo Tarsia; Oscar Massimiliano Epis; Massimo Puoti
Journal:  J Infect       Date:  2020-07-08       Impact factor: 6.072

10.  High Inflammatory Burden: A Potential Cause of Myocardial Injury in Critically Ill Patients With COVID-19.

Authors:  Yanjun Song; Peng Gao; Tian Ran; Hao Qian; Fan Guo; Long Chang; Wei Wu; Shuyang Zhang
Journal:  Front Cardiovasc Med       Date:  2020-07-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.